Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion.

Pharmacogenomics - 1 Jan 2025

Azizi Bayan, Lanfear David E, Luzum Jasmine A

Abstract excerpt

Metoprolol, a β1-selective blocker, is widely used for treating cardiovascular and non-cardiovascular conditions. Its pharmacokinetics (PK) and pharmacodynamics (PD) vary significantly between individuals, in part due to CYP2D6 genetic polymorphisms. Co-administration of CYP2D6 inhibitors can lead to phenotype-genotype discordance, known as phenoconversion, resulting in clinically significant changes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 CYP2D6 Inhibitors
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Metoprolol

Share to Phenotype

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 41392923
DOI: 10.1080/14622416.2025.2597182
PMCID: PMC12773468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion.PMID 41392923Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Addressing phenoconversion: the Achilles' heel of personalized medicine.Semantic proximity Read ↗

Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patientsSemantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.Semantic proximity Read ↗

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.Semantic proximity Read ↗

Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy Volunteers.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.